Loic Maurel, Md Email & Phone Number

LiSCo Health is a Consulting boutique integrating Market access, Commercial, M&A and Financing capabilities

Rennes, Bretagne, FR

Villeneuve-lès-Bouloc, FR

Good news - Zimmer Biomet acquires Vims

Trans-Hit Bio is the worldwide biospecimen access CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivaled worldwide partnered-network state-of-the-art academic biorepositories and clinical sites.

Toulouse, FR

M Capital Partners is a rapidly growing independent private equity company, specialized in financing small and medium businesses. M Capital Partners manages over €380 million and a portfolio of investments of 170 small and medium companies covering a wide range of industrial and service sectors. These portfolio companies employ over 9,500 people and.

Lausanne, CH

Debiopharm Group™ is a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management.For more information, please see www.debiopharm.com We are on Twitter. Follow @DebiopharmNews at.

Paris, FR

• Diaxonhit Group (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.After the.
• The new group reaches a critical mass, with €44 million in pro forma revenue in 2015.
• An innovative, integrated company, positioned in the fastest growing market segments, including molecular biology.
• A strong presence in complementary markets, in vitro diagnostics, life sciences research and corneal transplantation.
• One of the largest sales forces in France.
• Significant growth drivers, including an expanded portfolio of proprietary products and a strong international development.

Paris, FR

Exonhit changed its name into Diaxonhit after the acquisition of Ingen Biosciences in 2012.See full description in Diaxonhit.

Paris, Île-de-France, FR

Créée en 1997, France Biotech est l’institution française qui regroupe les principales entreprises des sciences dela vie et ses partenaires experts. France Biotech a pour mission d’accompagner le développement de cetteindustrie en France sur un terrain législatif et fiscal favorable. A l’origine du statut de Jeune Entreprise Innovante(JEI) mis en place.

CA

• Successfully built a Pharmaceutical Development Company on an innovative business model
• Recruited an experienced R&D, Manufacturing, F&A, Legal, BD&L team evaluating over 600 technologies
• Licensed-in a solid early (monoclonal antibodies) and late phase portfolio (vapreotide IR and SR formulations)
• Acquired a German Biotech start-up specialized in human monoclonal antibodies and cancer
• Negotiated and signed several out licensing deals e.g. CAT / Astra Zeneca, Salix, LG, Ranbaxy
• Achieved critical R&D milestones including 1 MAA, US & EU NDA filing, orphan drug designations, US INDs, phase 2 clinical trials in Hepatitis C and Alzheimer in Canada and phase 3 in Portal Hypertension in USA

CA

Following the acquisition of H3 Pharma in March 2005 by the Debio's Group in Lausanne, the company's name is now Debiovision.

Basel, Baselstadt, CH

• A sales budget responsibility of CAD $ 327 Mio.
• Scope of responsibility included: product management, GPs and specialty business sales forces, trade relations / customer service & distribution, generics, e-business, market research, scientific relations & convention.
• Reengineered marketing & sales organization (235 associates) resulting in a 1999 sales growth of 9.5% after 3 years without growth. Launched successfully several brands including Sandostatin (octreotide) LAR, Diovan.
• Managed one downsizing (30 associates) and two re-organizations.
• As a member of the Canadian Novartis Executive Committee contributed in setting overall country organization policy and direction, and strategic planning development processes.
• Following a worldwide business unit re-organization, nominated VP Marketing & Sales Neuroscience in 2001.

Basel, Baselstadt, CH

• Led the largest Novartis therapeutic franchise, supervising three global marketing groups.
• Spearheaded strategic reassessment of the CMR portfolio to focus on greatest growth opportunities, which included key brands in hypertension (Diovan), hypercholesterolemia, diabetes, asthma and COPD.
• Established Diovan as major growth driver and future No. 1 product of Novartis Pharmaceuticals
• Developed global vision and strategic direction that has resulted in the fastest growing brands within Novartis. Grew sales by SF 500 Mio during the first year and achieved SF 3 Bio in total sales.

Basel, Baselstadt, CH

• Supervised a team of International Marketing Managers in growing Ciba-Geigy’s CVS franchise to SF 1 400 Mio.
• Served as the International marketing representative on the global cardiovascular Therapeutic Area Review Board.
• Led the Global Diovan Launch Team and created vision and strategic plans to successfully launch Diovan the No. 1 company’s priority product.

• Developed and implemented strategic vision for Lotensin franchise resulted in global sales of over SF 1 Bio.
• Provided guidance to international project team to ensure market driven life cycle management.
• Served as global marketing representative on the newly formed Global Thrombosis Strategic Team.

• Developed and implemented strategic vision for Lotensin franchise resulted in global sales of over SF 1 Bio.
• Provided guidance to international project team to ensure market driven life cycle management.
• Served as global marketing representative on the newly formed Global Thrombosis Strategic Team.

• Promoted to regional medico-marketing manager supporting three district managers and a total of 65 representatives. Developed the regional medico-marketing strategy for the launch of two major brands.
• Responsibilities expanded to include training, recruiting, as well as providing business analyses and strategic direction to representatives, which positively impacted regional sales.

• Promoted cardiovascular and neuroscience brands to physicians, pharmacists and hospital administrators. Conducted educational programs for hospital and residents.
• Significantly increased sales in the territory.

• Managed the student insurance company and expanded membership by more than 15 times to reach 65,000 members, achieving annual sales of Euros 8 Mio. Promoted to Board member in 1979 and Chairman of the Board in 1982.

Md, Medecine

Baccaluréat D, Sciences Physiques